Advertisement

Guideline Edits Rooted in Science, Former USPSTF Member Says

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

“I don’t see this recommendation as differing in any substantial way from some others that we’ve made, where we suggested that patients talk with their clinicians, and the important messages here is that colorectal cancer screening works, that colorectal cancer screening reduces deaths from colorectal cancer,” said Douglas Owens, a who has rotated off the U.S. Preventive Services Task Force, and was involved in developing the colorectal cancer screening guideline published earlier this week.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.
Advertisement
Advertisement